Advertisement

Seattle Cancer Care Alliance opens Acute Clinical Evaluation Clinic

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Seattle Cancer Care Alliance opened an Acute Clinical Evaluation clinic. The three bed ACE clinic at SCCA’s South Lake Union campus serves individuals receiving cancer care at SCCA who experience cancer- and treatment-related pain and symptoms that surpass their ability to manage at home.

Originally planned for summer 2020, the ACE clinic opened ahead of schedule so that cancer patients would not have to visit an urgent care or emergency room for cancer-treatment related issues, especially important during the COVID-19 pandemic.

“We are committed to advancing the standard of cancer care, regionally and beyond, and the ACE clinic is a reflection of that commitment,” said Nancy Davidson, president and executive director of SCCA. “At SCCA, we provide comprehensive care, and the ACE clinic provides our patients with access to care from our highly trained, compassionate staff, specifically for their treatment-related pain and other symptoms.”

The ACE clinic is staffed by an oncology advanced practice provider and registered nurses specializing in cancer care. SCCA providers can refer patients to the clinic who need medical oncology care for pain and symptom management for issues including but not limited to gastrointestinal discomfort, fever/chills, dehydration, dizziness/lightheadedness, urinary tract infections, swallowing difficulties, swelling and skin conditions/rashes.

The ACE clinic does not provide emergency care and is limited to patients who are already receiving treatment from SCCA providers.

Advertisement
Advertisement
Table of Contents
Advertisement
Advertisement

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
Advertisement
Advertisement